VHL-alkyne is a VHL ligand for PROTAC synthesis..

VHL ligand 1 TFA is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein.

VGTI-A3-03 is a novel potent, highly virus-specific inhibitor of DENV replication with greatest activity against DENV serotype 2 (IC50=25 nM), directly bind DENV capsid protein.

VGSC blocker 1 is a potent, small molecule blocker of neonatal isoform of the VGSC subtype, Nav1.5 (nNav1.5), blocks INa peak currents 34.9% at 1 uM.

Vestipitant (GW597599) is a potent, selective, orally active NK1 receptor antagonist with pKi of 9.65.

Vestipitant (GW597599) is a potent, selective, orally active NK1 receptor antagonist with pKi of 9.65.

VERU-111 analogue 13f is a novel potent colchicine binding site inhibitor (CBSI) in tubulin with potential anticancer activities.

Vernakalant Hcl(RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic.

Veratramine(NSC17821; NSC23880) is useful as a signal transduction inhibitor for treating tumors.

Verapamil is a CYP3A inhibitor.

VER-50589 is a potent HSP90 inhibitor with IC50 of 21 nM for HSP90β.

Venlafaxine Hydrochloride is a dual ST and SLC6A2 (serotonin and noradrenalin re-uptake) inhibitor that displays ~ 30-fold higher affinity for ST (SERT) (Ki = 82 nm) than SLC6A2 (NET) (Ki = 2480 nM).

Velusetrag (TD-5108) is a potent, selective and oral 5-HT4 receptor agonist with pKi of 7.7, shows >500-fold selectivity over other 5-HT receptors.

Velusetrag (TD-5108) is a potent, selective and oral 5-HT4 receptor agonist with pKi of 7.7, shows >500-fold selectivity over other 5-HT receptors.

VEL-0230 (NC-2300) is a potent, selective cysteine Cathepsins inhibitor with IC50 of 284, 34.5 and 186 nM for Cat B, K and S, respectively.

Vecabrutinib (SNS-062) is a potent, reversible, non-covalent BTK inhibitor with IC50 of 2.9 and 4.4 nM for WT BTK and C481S BTK, respectively.

VDR 4-1 is a novel non-steroidal, small-molecule agonist of vitamin D receptor (VDR).

VCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection.

VCE-004.3 (VCE004.3) is a novel semi-synthetic cannabidiol derivative behaving as a dual PPARγ/CB2 agonist and CB1 receptor modulator, binds and activates PPARγ (IC50=3.5 uM) and CB2 receptors (pKi=6.69) and antagonizes CB1 receptor (pKi=5.61).

VB-82252 is a highly potent, orally active inhibitor of C. difficile toxins TcdA and TcdB, potently inhibits UDP glucose hydrolysis activity of TcdB (IC50=32 nM).

Varenicline Hcl(CP 526555;Champix) is a nicotinic receptor partial agonist; it stimulates nicotine receptors more weakly than nicotine itself does.

Vapreotide acetate is a synthetic analog of somatostatin for the treatment of variceal bleeding; also exhibits antitumor activity.

Vapendavir (BTA798) is a novel potent enteroviral capsid binder, inhibits EV71 replication of all isolates with mean EC50 of 0.7 uM.

Vanoxerine (GBR-12909, I-893, Boxeprazine) is a highly potent inhibitor of dopamine uptake in vitro in tissue slices obtained from rat neostriatum with IC50 of 40-50 nM, also inhibits norepinephrine uptake with IC50 of 560-2600 nM.

Valganciclovir (hydrochloride), the L-valyl ester of ganciclovir, is actually a prodrug for ganciclovir.

Valdecoxib (SC 65872) is a COX-2 selective inhibitor with an IC50 value of 5 nM.

Valategrast hydrochloride is a potent, α4β1 (VLA-4) and α4β7 dual antagonist..

Valategrast (R411), a small molecule antagonist of α4β1 integrin, represents a potential therapy for asthma

Valacyclovir is an antiviral agent that acts as a very potent inhibitor of viral DNA polymerase.

Vabicaserin hydrochloride is a 5-hydroxytryptamine 2C (5-HT2C) receptor-selective agonist with an EC50 of 8 nM.